[1] Iwakiri Y. Pathophysiology of portal hypertension[J]. Clin Liver Dis, 2014,18(2):281-291.
[2] 黄志寅, 高锦航. 保护门静脉——从病理生理到临床处理决策[J]. 临床肝胆病杂志, 2021,37(12):2760-2763.
[3] D′Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006,44(1):217-231.
[4] Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol, 2020,73(4):842-854.
[5] Trebicka J, Fernandez J, Papp M, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis[J]. J Hepatol, 2021,74(5):1097-1108.
[6] Hoshi H, Chu P S, Yoshida A, et al. Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis[J]. PLoS One, 2021,16(4):e250062.
[7] Arroyo V, Moreau R, Kamath P S, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers, 2016,2:16041.
[8] Masnou H, Luna D, Castillo E, et al. Prevalence and outcomes of acute-on-chronic liver failure among cirrhotic patients admitted for an acute decompensation[J]. Gastroenterol Hepatol, 2022,45(6):424-431.
[9] Medhat M A, Gushken F, Khaled T, et al. Acute-on-chronic liver failure in Egypt: an underestimated complication of liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2021,33(1S Suppl 1):e458-e463.
[10] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013,144(7):1426-1437, 1431-1437.
[11] Trebicka J, Gu W, Ibanez-Samaniego L, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS[J]. J Hepatol, 2020,73(5):1082-1091.
[12] Rogalski P, Zaborowska M, Mazur M, et al. Gastrointestinal hemorrhage as an acute-on-chronic liver failure trigger in cirrhotic patients[J]. Adv Clin Exp Med, 2022,31(8):863-871.
[13] Nakayama N, Uemura H, Uchida Y, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan[J]. Hepatol Res, 2018,48(4):303-312.
[14] Wang T, Tan W, Wang X, et al. Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis[J]. JHEP Rep, 2022,4(10):100529.
[15] Mahmud N, Sundaram V, Kaplan D E, et al. Grade 1 acute on chronic liver failure is a predictor for subsequent grade 3 failure[J]. Hepatology, 2020,72(1):230-239.
[16] Al-Mahtab M, Akbar S M, Garg H. Influence of variceal bleeding on natural history of ACLF and management options[J]. Hepatol Int, 2016,10(3):436-439.
[17] Garg H, Kumar A, Garg V, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure[J]. J Gastroenterol Hepatol, 2013,28(8):1361-1367.
[18] Bosch J, Abraldes J G, Albillos A, et al. Portal hypertension: recommendations for evaluation and treatment: consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases(CIBERehd)][J]. Gastroenterol Hepatol, 2012,35(6):421-450.
[19] Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding[J]. Gastroenterology, 2014,146(2):412-419.
[20] Sharma S, Agarwal S, Saraya A, et al. Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)[J]. Hepatology international, 2022,16(5):1234-1243.
[21] Gustot T, Fernandez J, Garcia E, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology, 2015,62(1):243-252.
[22] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis[J]. The New England Journal of Medicine, 2010,362(9):823-832.
[23] 中华医学会消化病学分会微创介入协作组. 经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识(2022年版)[J]. 中华肝脏病杂志, 2022,30(12):1349-1364.
[24] Garcia-Pagan J C, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study[J]. J Hepatol, 2013,58(1):45-50.
[25] Garcia-Pagan J C, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010,362(25):2370-2379.
[26] Hernandez-Gea V, Procopet B, Giraldez A, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study[J]. Hepatology, 2019,69(1):282-293.
[27] Rodrigues S G, Mendoza Y P, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations[J]. JHEP Rep, 2020,2(1):100063.
[28] Villanueva C, Torres F, Sarin S K, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis[J]. Journal of Hepatology, 2022,77(4):1014-1025.
[29] Kumar M, Kainth S, Choudhury A, et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial[J]. Hepatol Int, 2019,13(6):800-813.
[30] Mookerjee R P, Pavesi M, Thomsen K L, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure[J]. J Hepatol, 2016,64(3):574-582.
[31] Rossle M. TIPS: 25 years later[J]. J Hepatol, 2013,59(5):1081-1093.
[32] Trebicka J. Does transjugular intrahepatic portosystemic shunt stent differentially improve survival in a subset of cirrhotic patients?[J]. Seminars in liver disease, 2018,38(1):87-96.
[33] Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J]. Hepatology, 2004,40(4):793-801.
[34] 张明. 经颈静脉肝内门体分流术在食管胃静脉曲张出血治疗中的进展[J]. 中国实用内科杂志, 2022,42(10):796-799.
[35] Nicoara-Farcau O, Han G, Rudler M, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data[J]. Gastroenterology, 2021,160(1):193-205.
[36] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII-Renewing consensus in portal hypertension[J]. Journal of Hepatology, 2022,76(4):959-974.
[37] Kumar R, Kerbert A, Sheikh M F, et al. Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding[J]. J Hepatol, 2021,74(1):66-79.
[38] Maimone S, Saffioti F, Filomia R, et al. Predictors of re-bleeding and mortality among patients with refractory variceal bleeding undergoing salvage transjugular intrahepatic portosystemic shunt (TIPS)[J]. Dig Dis Sci, 2019,64(5):1335-1345. |
